Back to Search
Start Over
Checkpoint Inhibition in Non-Hodgkin's Lymphoma
- Source :
- Oncology research and treatment. 40(11)
- Publication Year :
- 2017
-
Abstract
- As patients continue to die from malignant lymphoma, novel treatment options continue to be warranted. To successfully grow and spread, tumor cells need to escape the immune system; therefore, the augmentation or restoration of immune effectors against the malignant cell could be of great value, as shown, e.g., for allogeneic transplantation. A deepened understanding of the regulation of activation and inhibition of the T cell-based effector mechanisms has led to the development of drugs that are able to modify specific checkpoints of this system and thereby raise an immune response against tumor cells. With dramatic responses observed in Hodgkin's disease (HD), interest has risen to explore these drugs in non-Hodgkin's lymphoma (NHL). Available data underline the potential of checkpoint inhibitors in a variety of lymphoma entities, such as primary mediastinal B cell lymphoma (PMBCL) or central nervous system (CNS) lymphoma, and there is hope that a significant proportion of patients will finally benefit. However, intensive efforts are needed to develop optimal screening tools, combinations, and sequences to explore the full potential of these new classes of therapeutic agents.
- Subjects :
- 0301 basic medicine
Cancer Research
Allogeneic transplantation
T cell
T-Lymphocytes
Antineoplastic Agents
Disease
03 medical and health sciences
0302 clinical medicine
Immune system
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
medicine
Effector
business.industry
Lymphoma, Non-Hodgkin
Antibodies, Monoclonal
Hematology
medicine.disease
Ipilimumab
Lymphoma
Non-Hodgkin's lymphoma
030104 developmental biology
medicine.anatomical_structure
Nivolumab
Oncology
030220 oncology & carcinogenesis
Cancer research
Tumor Escape
Primary mediastinal B-cell lymphoma
business
Rituximab
Subjects
Details
- ISSN :
- 22965262
- Volume :
- 40
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Oncology research and treatment
- Accession number :
- edsair.doi.dedup.....bcbe1bdd42c480a7153c5687a691778f